Rinvoq ER 45 MG tablet UU 28S
Ended Awarded Last action
- Contract number
- SPE2DR26FV291
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $42,915
Award facts
- Contract value 100% obligated
- $42,914.69 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $42,914.69 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 6, 2026, for RINVOQ ER 45 MG tablets (28-count unit dose packaging). The contract, with an ultimate completion date of January 7, 2026, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with parent company Cencora, Inc. (doing business as AmerisourceBergen) providing organizational oversight. RINVOQ (upadacitinib) is a JAK inhibitor used primarily for rheumatoid arthritis and other autoimmune conditions, representing the type of specialty pharmaceutical products the Defense Logistics Agency Medical Supply Chain procures to support military treatment facilities and veteran healthcare programs.
This delivery order is executed under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), which serves as the primary vehicle for supplying comprehensive pharmaceutical products and medical commodities to military healthcare systems worldwide. AmerisourceBergen's federal contract portfolio demonstrates consistent capability in fulfilling competitive procurements for brand-name and generic medications, vaccines, and specialty medical supplies across multiple therapeutic domains. The company's position as a critical vendor in the federal pharmaceutical supply chain reflects its established role in supporting Defense Health Agency requirements and broader military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FV291?
SPE2DR26FV291 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FV291 worth?
The government has obligated $42,915 on SPE2DR26FV291.
Is contract SPE2DR26FV291 an order under another contract?
Yes. SPE2DR26FV291 is a delivery order under SPE2DR25D1053, an indefinite delivery contract.
Was contract SPE2DR26FV291 competed?
The extent of competition for SPE2DR26FV291 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award